10-QPeriod: Q2 FY2025

Cencora, Inc. Quarterly Report for Q2 Ended Mar 31, 2025

Filed May 7, 2025For Securities:COR

Summary

Cencora, Inc. reported a strong first quarter for fiscal year 2025, demonstrating robust revenue growth driven by its U.S. Healthcare Solutions segment. Total revenue for the quarter increased by 10.3% year-over-year, reaching $75.5 billion, with the U.S. segment experiencing a significant 11.4% rise. This growth was bolstered by strong unit volume increases, notably a 36.1% surge in sales of GLP-1 class drugs for diabetes and weight loss, totaling $2.2 billion. Net income attributable to Cencora, Inc. rose to $717.9 million, a substantial increase from $420.8 million in the prior year's first quarter, translating to diluted earnings per share of $3.68. The company also benefited from a substantial gain related to antitrust litigation settlements, contributing significantly to the increase in gross profit. Despite increased operating expenses, largely due to the recent acquisition of Retina Consultants of America (RCA) and associated integration costs, the company managed to expand its operating income by 87.3% year-over-year to $1,036.2 million. Cencora also highlighted continued capital allocation through share repurchases and dividend payments.

Financial Highlights

56 data points
Beta

Revenue

$75.45B

4.1% Gross Margin

Net Income

$717.87M

1.0% Net Margin

EPS (Diluted)

$3.68

Total Assets

$71.19B

Cash & Equivalents

$1.98B

Free Cash Flow

$3.22B

Financial Statements
Beta
Revenue$75.45B
Cost of Revenue$72.39B
Gross Profit$3.06B
SG&A Expenses$1.60B
Operating Expenses$1.72B
Operating Income$1.04B
Net Income$717.87M
EPS (Basic)$3.70
EPS (Diluted)$3.68
Shares Outstanding (Basic)193.80M
Shares Outstanding (Diluted)195.09M

Key Highlights

  • 1Revenue increased by 10.3% to $75.5 billion in Q1 FY25, driven by the U.S. Healthcare Solutions segment which saw an 11.4% rise.
  • 2Sales of GLP-1 class drugs for diabetes and weight loss grew by 36.1% ($2.2 billion) year-over-year, a key driver of revenue.
  • 3Net income attributable to Cencora, Inc. significantly increased to $717.9 million from $420.8 million in Q1 FY24.
  • 4Diluted earnings per share improved to $3.68, up from $2.09 in the prior year's comparable quarter.
  • 5Gross profit saw a substantial increase of 20.6% to $3.1 billion, boosted by higher sales and significant gains from antitrust litigation settlements.
  • 6Operating income grew by a strong 87.3% to $1.04 billion, reflecting improved operational efficiency and revenue growth, despite higher operating expenses.
  • 7The company completed the acquisition of Retina Consultants of America (RCA) in January 2025, contributing to increased goodwill and integration expenses.

Frequently Asked Questions

Revenue increased by 10.3% year-over-year to $75.5 billion, primarily due to strong performance in the U.S. Healthcare Solutions segment. This growth was driven by increased unit volumes, particularly a significant rise in sales of GLP-1 class drugs for diabetes and weight loss, which grew by 36.1% ($2.2 billion). Increased sales of specialty products to physician practices and health systems also contributed to the growth.

The acquisition of RCA, completed in January 2025, contributed to increased revenue and goodwill on the balance sheet. It also led to higher operating expenses, specifically acquisition-related deal and integration expenses, and contributed to the growth in the U.S. Healthcare Solutions segment's operating income. The financial statements reflect RCA's results of operations since the acquisition date.

Cencora's accrued litigation liability related to opioid settlements was $4.7 billion as of March 31, 2025. This liability is expected to be paid over the next 14 years, with approximately $416.5 million estimated to be paid before March 31, 2026. The company continues to defend itself in ongoing litigation and investigations.

Cencora has a diversified debt structure, including fixed-rate and variable-rate debt. In the first quarter of fiscal year 2025, the company issued new senior notes and a term loan, totaling $1.8 billion and $1.5 billion respectively, to finance the RCA acquisition. The company has significant availability under its credit facilities and generated $632.5 million in cash flow from operations during the six months ended March 31, 2025, indicating strong liquidity to manage its obligations, including debt repayment and dividends.